Where Do 1.5 Million Datapoints Lead Us in Guiding Antithrombotic Treatment of Lower Extremity Arterial Disease?

Eur J Vasc Endovasc Surg. 2023 Aug;66(2):220. doi: 10.1016/j.ejvs.2023.05.012. Epub 2023 May 16.

Authors

Willemien van de Water¹, Bob Siegerink²

Affiliations

¹ Department of Vascular and Endovascular Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. Electronic address: Willemien.van.de.water@mumc.nl.
² Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands.

PMID: 37196915
DOI: 10.1016/j.ejvs.2023.05.012

No abstract available

Publication types

Comment

MeSH terms

Anticoagulants
Fibrinolytic Agents / adverse effects
Humans
Lower Extremity / blood supply
Peripheral Arterial Disease* / diagnostic imaging
Peripheral Arterial Disease* / drug therapy
Platelet Aggregation Inhibitors
Vascular Diseases*

Substances

Fibrinolytic Agents
Platelet Aggregation Inhibitors
Anticoagulants